Cagrilintide is a long-acting analog of amylin, a hormone co-secreted with insulin by the pancreas that plays a role in satiety and gastric emptying. It’s become one of the most closely watched compounds in the metabolic-peptide space because of how it’s being paired with GLP-1 agonists rather than used alone.
Amylin’s Distinct Mechanism
GLP-1 agonists like semaglutide and tirzepatide primarily slow gastric emptying and increase satiety signaling through the incretin pathway. Amylin analogs work through a related but separate mechanism, acting on amylin receptors in the brainstem to reduce food intake and slow gastric emptying via a different signaling route. Combining the two pathways is the logic behind dual-agonist research combinations like CagriSema.
The Muscle-Preservation Angle
One of the most consistent criticisms of GLP-1-driven weight loss is that a meaningful share of the loss can come from lean mass rather than fat. Amylin-pathway compounds are of specific research interest partly because early data suggests a potentially more favorable fat-to-lean-mass loss ratio compared to GLP-1 monotherapy, though this remains an active area of investigation rather than settled science.
How It’s Being Researched in Combination
Cagrilintide is most often discussed in the research literature alongside semaglutide in a fixed-ratio combination, reflecting the broader industry trend toward multi-mechanism metabolic compounds rather than single-pathway agents.
Sourcing
Cagrilintide is a research compound, not an FDA-approved medication, and is available through the following vendors.